Clinical Trials Logo

HER2-positive Carcinoma clinical trials

View clinical trials related to HER2-positive Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03133988 Approved for marketing - Clinical trials for HER2-positive Breast Cancer

Margetuximab Expanded Access Program

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.

NCT ID: NCT03109977 Completed - Clinical trials for HER2-positive Carcinoma

Imaging With a New Agent That Finds a Cancer Protein Called HER2

Start date: March 31, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.